Active Clinical Trials

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

By April 24, 2017 No Comments


Mesothelioma|Adenocarcinoma of Lung|Pancreatic Neoplasms

Estimated Enrollment: 55

Age Group: 18 Years to 99 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment

Study ID Numbers: 110160|11-C-0160

Study First Received: May 27, 2011

Last Updated: April 20, 2017

Estimated Primary Completion Date: August 3, 2016


Primary Outcome Measures:

Objective response rate stratified by tumor type|SS1P antibody formation|Grade and description of adverse events|determine RP2D in drug lot FIL129J01|Overall survival|Progression-free survival|Duration of response

Sponsors and Collaborators:

National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)

Website Link:

Leave a Reply

Call Now ButtonCall Now